Castle Biosciences (CSTL) Expected to Announce Quarterly Earnings on Monday

Castle Biosciences (NASDAQ:CSTL) is expected to release its Q1 2025 earnings data after the market closes on Monday, May 5th. Analysts expect Castle Biosciences to post earnings of ($0.08) per share and revenue of $80.40 million for the quarter.

Castle Biosciences Stock Up 0.2 %

CSTL opened at $19.35 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.64 and a current ratio of 7.78. The company has a market capitalization of $558.15 million, a PE ratio of 96.75 and a beta of 1.11. The stock’s fifty day moving average is $20.43 and its 200-day moving average is $26.19. Castle Biosciences has a one year low of $16.97 and a one year high of $35.84.

Insider Buying and Selling

In other news, insider Derek J. Maetzold sold 22,639 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $20.12, for a total value of $455,496.68. Following the completion of the sale, the insider now owns 80,465 shares of the company’s stock, valued at $1,618,955.80. This trade represents a 21.96 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Daniel Bradbury sold 7,867 shares of the stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $28.17, for a total value of $221,613.39. The disclosure for this sale can be found here. In the last 90 days, insiders sold 35,321 shares of company stock valued at $774,644. Company insiders own 7.20% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have commented on CSTL. Guggenheim set a $30.00 price target on shares of Castle Biosciences and gave the stock a “buy” rating in a research report on Friday, March 28th. Robert W. Baird increased their target price on shares of Castle Biosciences from $36.00 to $37.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $38.75.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.